Skip to primary content
Skip to secondary content

Biotech 365

Main menu

  • Biotech 365
  • Companies
  • Healthcare Investors
    • Healthcare LPs
  • Healthcare Investors Matchmaking
  • Free DEMO
  • Services
    • Preclinical Studies Database
    • Scientific Due Diligence
    • CRO & CDMO Database
  • Contact

Tag Archives: Jennifer Sengenès

PEP Therapy – innovative peptides as targeted therapies for oncology

Posted on by

PEP Therapy is a biotech company developing targeted therapies for the treatment of severe diseases, with an initial focus on cancer.

PEP Therapy – innovative peptides as targeted therapies for oncology

PEP Therapy Continue reading →

Posted in Biotech Companies, Biotech Companies France | Tagged Angelita Rebollo, Antoine Prestat, caspase, caspase activation, Cell Penetrating and Interfering Peptide, Cell Penetrating and Interfering Peptides, Cell Penetrating Interfering Peptide, Cell Penetrating Interfering Peptides, Cell Penetrating Peptide, Cell Penetrating Peptides, chemotherapies, chemotherapy, Chronic lymphocytic leukemia, CLL, CP&IP, CP&IP - DPT-PEP1, Didier Decaudin, DPT, DPT-PEP1, Fariba Némati, innovative peptides as targeted therapies for oncology, Jean-Loup Romet Lemonne, Jennifer Sengenès, PEP Therapy, PEP Therapy - innovative peptides as targeted therapies for oncology, PEP-Therapy SAS, peptide, peptides, protein-protein interaction, protein-protein interactions, Short Interfering peptide, Short Interfering peptides

        Services              Healthcare Investors Database              FAQs               CGU               Biotech & Pharma News             Contact
Proudly powered by WordPress